

**Monthly Oncology Tumor Boards:  
A Multidisciplinary Approach to Individualized Patient Care**

**Prostate Cancer: Castrate Resistant**

**Andrew J. Armstrong, MD, ScM**

*Duke Cancer Institute*

**Bridget Koontz, MD**

*Duke Cancer Institute*

May 17, 2016

**Moderated by Mark Geisler**

*NCCN, Conferences and Meetings Department*

This activity is supported by educational grants from BTG; Bristol-Myers Squibb.; Celgene Corporation; Genomic Health, Inc.; Lilly; Merck; Novartis Oncology; Prometheus Laboratories; Spectrum Pharmaceuticals, and by a grant from AstraZeneca, and an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

**Q&A and Technical Support**

- Please use the Q&A feature on the right-hand portion of your screen for any clinical questions and logistical concerns you have regarding the session. This is the only online method of communicating questions or concerns. Should you need additional assistance please e-mail [education@nccn.org](mailto:education@nccn.org) or call 215-690-0300 and ask to be connected with someone in the NCCN Conferences and Meetings Department.
- While NCCN is pleased to respond to as many questions as possible during this webinar, NCCN will not be able to respond to your individual questions of a clinical nature after the webinar has concluded. We are also not able to offer recommendations on patient care regarding specific cases.



National  
Comprehensive  
Cancer  
Network®

## Attendance Lists & Registration

- If you are participating with a group of peers, a list of everyone who attended in your group must be submitted within two weeks of the activity in order for the participants to be eligible to receive credit. This list is in addition to individual registration. Attendee lists will not be accepted after two weeks post-activity.
- Lists can be sent to [education@nccn.org](mailto:education@nccn.org) and should contain full contact information for each participant, including first and last name, credentials, mailing address, phone number, and e-mail address.
- If you have not individually registered, please register at: <http://www.cvent.com/d/6fqrc4>.



National  
Comprehensive  
Cancer  
Network®

## Accreditation Information

### Intended Audience

This webinar series is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

### Learning Objectives

Following this program, participants should be able to:

- Recognize the role of recently approved targeted therapies for patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Evaluate current therapeutic options for patients with relapsed/refractory CLL and effectively incorporate newly approved therapies into their treatment plan



## Accreditation Information

### Physicians

The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Nurses

National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.



## Accreditation Information

### Pharmacists

#### **Accreditation Statement**



National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**Type of Activity:** Knowledge

**UAN:** 0836-0000-16-023-L01-P

**Credit Designation:** National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

**Attention Pharmacists:** ACPE and NABP have implemented CPE Monitor as a way to electronically track all ACPE-accredited CPE Units. In order to receive credit for this activity, please enter your six-digit NABP e-profile ID and birth date in the format of MMDD as part of the Overall Evaluation. If you have not already done so, please complete your e-profile at <http://www.nabp.net> to obtain your NABP e-Profile ID.

To comply with ACPE standards, pharmacists must complete all activity requirements within **30 days** of the live event date.



## Accreditation Information

### How to Claim Credit:

**Within 5 business days after this educational program**, you will receive an e-mail with information on how to claim credit for this activity. A statement of credit will be issued only upon completion of the activity evaluation form & immediate post-test within **30 days** of the activity date. A certificate will be electronically generated immediately upon completion of the evaluation.

All credit claiming must be done online through NCCN's continuing education portal at <https://education.nccn.org/node/78402>.

Should you not receive an e-mail within 5 days, please contact us at [education@nccn.org](mailto:education@nccn.org).



## Accreditation Information

- It is required by the ACCME that all educational activities are designed to change participant **competence, performance, or patient outcomes**.
- To meet this requirement, NCCN asks that all participants complete the outcomes measures described below:
  - The post-test and evaluation as indicated in e-mail you will receive within 3-5 business days of the conclusion of this activity. This is required to receive credits or your certificate of completion. You must be registered in advance to receive credits or certificate. Certificates will be generated automatically upon successful completion of this step.
    - There will be a separate WebEx evaluation at the conclusion of this program, which is optional and does not go to NCCN.
  - The follow-up post test (to be sent 30 days after the activity has ended to demonstrate an increase in participant competence)
- NCCN greatly appreciates your compliance with completing the aforementioned post-test and surveys. All of these measures will be available by logging into your account at <http://education.nccn.org>. Reminder e-mails will be sent to the participants via e-mail. If you have any questions or concerns, please e-mail [education@nccn.org](mailto:education@nccn.org).

## Disclosures

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

## Faculty Disclosures

### Disclosure of Relevant Financial Relationships

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME's, ANCC's, and ACPE's Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME's Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

### Faculty Disclosures

The faculty listed below have disclosed the following relevant financial relationships:

#### **Andrew J. Armstrong, MD, ScM**

Astellas and Medivation, Inc.: Grant/Research Support; Scientific Advisor  
Bayer HealthCare: Grant/Research Support; Scientific Advisor  
Dendreon Corporation: Grant/Research Support; Product/Speakers Bureau  
Janssen Pharmaceutica Products, LP: Grant/Research Support  
Novartis Pharmaceuticals Corporation: Grant/Research Support  
Pfizer Inc. Grant/Research Support  
sanofi-aventis U.S.: Grant/Research Support; Product/Speakers Bureau

#### **Bridget Koontz, MD**

Blue Earth Diagnostics Limited: Scientific Advisor  
Janssen Pharmaceutica Products, LP: Grant/Research Support  
UpToDate, Inc.: Royalty Income



## NCCN Staff Disclosures

### NCCN Staff Disclosures

The activity planning staff listed below has no relevant financial relationships to disclose:

**Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Kathy Smith, CMP, CHCP; Jennifer McCann Weckesser**

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:

**Deborah Freedman-Cass, PhD; Dorothy Shead, MS**



## Faculty Biography

**Andrew J. Armstrong, MD, ScM**, is Associate Professor of Medicine and Co-Director of the Clinical Research Program at Duke Cancer Institute. He is a medical oncologist and an internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly prostate cancer.

Dr. Armstrong trained at Duke University as a biomedical engineer and received his medical degree at the University of Virginia School of Medicine. He completed a residency in internal medicine at the Hospital of the University of Pennsylvania and a fellowship at Johns Hopkins Hospital, followed by public health clinical investigation training at the Bloomberg School of Public Health. Dr. Armstrong joined Duke's faculty in 2006, where he has subsequently remained.

As a clinical and translational investigator, Dr. Armstrong's research examines experimental therapeutics for patients with advanced genitourinary malignancies, particularly with a focus on prostate cancer and the investigation of biomarkers of response and benefit. His research for circulating tumor cell biology and epithelial plasticity is funded by the US Department of Defense, the Prostate Cancer Foundation and Movember, the NIH, and the American Cancer Society. He has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of mTOR inhibitors and PI3 kinase inhibitors, immunomodulatory agents, hormonal therapies, and anti-angiogenic agents. He also is heavily involved in the leadership of several phase 3 studies in advanced prostate cancer (dasatinib, tasquinimod, enzalutamide) in CRPC and is principal investigator on 8 investigator-initiated clinical trials and approximately 12 industry or cooperative group sponsored clinical trials.

Dr. Armstrong is a member of the NCCN Prostate Cancer Panel. He also contributes to the NCCN Oncology Research Program (ORP) by serving on the Enzalutamide Scientific Review Committee and the Temsirolimus Scientific Advisory Board and Scientific Review Committee.



National  
Comprehensive  
Cancer  
Network®

## Faculty Biography

**Bridget Koontz, MD**, is Associate Professor in the Department of Radiation Oncology at Duke University Medical Center and Medical Director of Radiation Oncology Services at Durham Regional Hospital.

Dr. Koontz earned her medical degree from Harvard Medical School. She completed an internship in internal medicine at UNC-Chapel Hill Hospitals and a residency in radiation oncology at Duke University Medical Center, during which she served as Chief Resident in her final year. She went on to complete a fellowship in low-dose rate (LDR) brachytherapy through the American Brachytherapy Society and the Seattle Prostate Institute.

Dr. Koontz's research and clinical interest is in genitourinary cancers, with a specific focus on minimizing the side effects of radiotherapy in the treatment of prostate cancer. Collaborating with a multidisciplinary team, her laboratory studies the mechanisms of radiation-induced erectile dysfunction and tests interventions to treat and prevent this devastating side effect. As part of her work, Dr. Koontz works to improve patient-provider interactions when discussing how cancer therapies affect sexuality and intimacy during and after treatment.

Dr. Koontz is a member of several professional organizations, including the American Society for Radiation Oncology, the American Society of Clinical Oncology, the American Urological Association, the International Society of Sexual Medicine, and the Sexual Medicine Society of North America. She also serves on a number of committees, including the Sexual Medicine Society of North America Basic Science Committee, the ASTRO Education Committee, the NRG Cancer Prevention and Control Committee, and the NRG Cooperative Group GU Steering Committee. Additionally, she serves as Co-Chair for the Integrating the Healthcare Enterprise – Radiation Oncology (IHE-RO) Planning Committee and Vice-Chair for the ASTRO Clinical Translational Basic Science Advisory Committee.

In addition to her professional memberships, Dr. Koontz serves as Associate Senior Editor of the *International Journal of Radiation Oncology, Biology, Physics*. She also has served as a reviewer for a number of prominent academic journals, including *European Urology*, *Journal of Sexual Medicine*, *Practical Radiation Oncology*, *Cancer and Prostatic Disease*, the *Journal of Urology*, and *Annals of Urology*.

## Castrate-Resistant Prostate Cancer: Case Studies and NCCN Guidance

**Andrew J. Armstrong, MD, ScM, FACP**

**Bridget Koontz, MD**

*Duke Cancer Institute*

May 2016

## Learning Objectives

- Outline novel therapies for castrate-resistant prostate cancer (CRPC) that received approval in recent years
- Assess available treatment options appropriate to different settings based on symptoms, overall health, and risk-benefit ratios


## Illustrative Case #1

- 70yo white male with prostate cancer:
  - October 2004 – cT2b G4+3 7/10, 50% to 75% cores, PSA 15 ng/mL
  - Metastatic workup: negative
- February 2005 – Combined brachytherapy (Pd103) and external beam radiation therapy (EBXRT [IMRT])
- 2005 through 2006 – GnRH agonist monotherapy
  - PSA decreases to <0.01 but rises 6 years later in the setting of normal testosterone levels to 2.6
  - Restaging scans are normal, no evidence of local recurrence or adenopathy, visceral or bony metastases
- August 2012 – Bicalutamide and leuprolide
  - PSA dropped <0.1 ng/mL
- Late 2012-early 2013 – PSA rise; rapid PSA doubling time (PSADT) = 3 months





### NCCN Schema: M0 CRPC




- No level 1 evidence with survival data
- Improved response and PFS (PSA, radiographic) with enzalutamide over bicalutamide
- Unclear if early M0 vs standard M1 CRPC use of enzalutamide is more advantageous
- Ongoing phase 3 trials in M0 CRPC setting will address this, and trial enrollment is encouraged

© National Comprehensive Cancer Network, Inc.® 2016, All Rights Reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

## Secondary hormonal manipulations (excluding abiraterone, enzalutamide)

- Median duration of PSA response
  - 3-6 months, but some respond for >1 year
- Objective responses uncommon
- STRIVE trial is first randomized trial to include M0 CRPC patients

## STRIVE: Enzalutamide vs. Bicalutamide



Similar results observed with TERRAIN in M1 CSPC (n=375):  
 median PFS 5.8→15.7 months with enzalutamide vs. bicalutamide  
 (HR = 0.44; 95% CI, 0.34-0.57;  $P < .0001$ ), time to FACT-P deterioration 8.5→13.8 months

CI = confidence interval; HR = hazard ratio; NR = not reached.

Penson D, Armstrong AJ et al, JCO 2016

ClinicalTrials.gov identifier: NCT01664923.

AUA Annual Meeting  
 May 15 - 19, 2015  
 New Orleans, LA, USA


## Activity in M0 CRPC

End Point	Enzalutamide		Bicalutamide		HR	95% CI	P
	No./Total (%)	95% CI	No./Total (%)	95% CI			
Overall	(n = 198)		(n = 198)				
Median PFS, months	19.4	16.5 to NR	5.7	5.6 to 8.1	0.24	0.18 to 0.32	< .001*
Median time to PSA progression, months	NR	19.4 to NR	8.3	5.7 to 8.5	0.19	0.14 to 0.26	< .001†
PSA response							
Patients with ≥ 1 postbaseline PSA assessment	192		195				
Confirmed PSA decline ≥ 50% from baseline	156/192 (81)		61/195 (31)				< .001†
Confirmed PSA decline ≥ 90% from baseline	124/192 (65)		17/195 (9)				< .001
rPFS	198		198				
Median, months	NR	NR to NR	11.2	8.4 to 16.6	0.30	0.21 to 0.44	< .001
Nonmetastatic	(n = 70)		(n = 69)				
Median PFS, months†	NR	19.4 to NR	8.6	8.1 to 11.1	0.24	0.14 to 0.42	< .001
Median time to PSA progression, months	NR	NR to NR	11.1	8.4 to 13.9	0.18	0.10 to 0.34	< .001
PSA response							
Patients with ≥ 1 postbaseline PSA assessment	66		69				
Confirmed PSA decline ≥ 50% from baseline	60/66 (91)		29/69 (42)				< .001
Confirmed PSA decline ≥ 90% from baseline	50/66 (76)		8/69 (12)				< .001
Median rPFS, months	NR	NR to NR	NR	14.1 to NR	0.24	0.10 to 0.56	< .001

Penson D, Armstrong AJ et al, JCO 2016

## Illustrative Case #1 (cont)


- Taken off antiandrogen but no withdrawal response
  - testosterone 25 ng/dL
- May 2013 – 11.2 ng/mL
- Imaging:
  - Bone scan: widespread osseous metastases
  - CT AP: no visceral involvement (subcentimeter pulmonary nodules and mesenteric nodes)
- Asymptomatic



### NCCN Guidelines Version 2.2016 Prostate Cancer


#### NCCN Schema: M1 CRPC

##### SYSTEMIC THERAPY FOR M1 CRPC




© National Comprehensive Cancer Network, Inc.® 2016, All Rights Reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

## Multiple Treatment Options Are Now Available for Men With Metastatic Prostate Cancer



## Pattern of Spread is Important for Prognosis





**Note:** the expected survival of men with mCRPC and lung metastases is similar to that of men with mCRPC and bone metastases, while men with liver metastases have the poorest survival

Halabi et al JCO 2016

# Zoledronic Acid


Parameter	Core plus Extension Phase		
	Zoledronic Acid, 4 mg (n = 214)	Placebo (n = 208)	P Value
Patients with $\geq 1$ Skeletal-Related Event (%)	81 (38)	101 (49)	0.028
Median Time to First Skeletal-Related Event (Days)	488	321	0.009
Mean Incidence of Skeletal-Related Events per Year	0.77	1.47	0.005
Multiple-Event Analysis (Risk Ratio)	0.64	—	0.002
BPI Score (Mean Increase from Baseline)*	0.58	1.05	0.024
Analgesic Score (Mean Increase from Baseline)*	1.04	1.17	0.491



Saad et al Clin GU Cancers 2005, JNCI 2004

# Denosumab: RANKL mAb


Positive phase III data in solid tumors to prevent SREs



Roodman et al Nature Medicine 2007


## Phase 3 RCTs of Osteoclast-Targeted Therapy: *Time to First Skeletal Related Event*

Zoledronic acid versus Placebo



Saad et al (2002) J Natl Cancer Inst


Denosumab versus Zoledronic acid




Fizazi et al (2011) Lancet

## Phase 3 RCT of Denosumab versus Zoledronic Acid

Overall Survival



Time to Disease Progression



Fizazi et al Lancet 2011

## Risk / Benefit Profile for Denosumab vs. Zoledronic Acid

	Zoledronic acid (n=951)	Denosumab (n=950)
Total confirmed events	386 (41%)	341 (36%)
Radiation to bone	203 (21%)	177 (19%)
Pathological fracture	143 (15%)	137 (14%)
Spinal cord compression	36 (4%)	26 (3%)
Surgery to bone	4 (<1%)	1 (<1%)


Acute phase reactions: 18 vs. 8%  
favoring denosumab

Renal impairment: 15 vs. 16%

	Zoledronic acid (n=945)	Denosumab (n=943)	p value*
<b>Overall safety summary</b>			
Any adverse event	918 (97%)	916 (97%)	1.00
Adverse events occurring with $\geq 20\%$ frequency in either treatment group			
Anaemia	341 (36%)	337 (36%)	0.89
Back pain	287 (30%)	304 (32%)	0.40
Decreased appetite	274 (29%)	267 (28%)	0.76
Nausea	245 (26%)	272 (29%)	0.16
Fatigue	222 (23%)	257 (27%)	0.06
Constipation	251 (27%)	236 (25%)	0.46
Bone pain	245 (26%)	235 (25%)	0.63
Asthenia	239 (25%)	239 (25%)	1.00
Arthralgia	202 (21%)	194 (21%)	0.69
Pain in extremity	196 (21%)	197 (21%)	0.95
Peripheral oedema	174 (18%)	192 (20%)	0.30
Adverse events leading to treatment discontinuation	138 (15%)	164 (17%)	0.10
CTCAE grade 3 or 4 adverse events	628 (66%)	678 (72%)	0.01
Serious adverse events	568 (60%)	594 (63%)	0.20
Fatal adverse events	276 (29%)	283 (30%)	0.72
<b>Adverse events of interest</b>			
Infectious adverse events†	375 (40%)	402 (43%)	0.21
Cumulative osteonecrosis of the jaw (total)	12 (1%)	22 (2%)	0.09
Year 1	5 (1%)	10 (1%)	-
Year 2	8 (1%)	22 (2%)	-
Hypocalcaemia	55 (6%)	121 (13%)	<0.0001
New primary malignant disease	10 (1%)	18 (2%)	0.13

Fizazi et al Lancet 2011


## CALGB/ALLIANCE 90202: RCT of Early Versus Standard Zoledronic Acid



SRE, skeletal-related event

Smith et al JCO 2014

## STAMPEDE: Zoledronic Acid




## NCCN Guidance for Bone Anti-Resorptive Therapies

- Both zoledronic acid and denosumab are effective at delaying the time to skeletal related events (spinal cord compression, radiation, surgery to bone, pathologic fractures) in men with mCRPC
- **No known clinical activity in hormone-sensitive disease and not recommended in this setting regardless of bone metastases**
- These agents do not improve survival or delay progression-free survival
- Risk of osteonecrosis of the jaw (ONJ) increases over time and with more frequent dosing


NCCN Guidelines for Prostate Cancer, V2.2016.



## Sipuleucel-T: Mechanism of Action



## IMPACT Overall Survival



Kantoff et al NEJM 2010

## IMPACT: Sipuleucel-T Trend Toward Greater Survival Benefit With Lower Baseline PSA

	Baseline PSA, ng/mL			
	≤22.1 (n=128)	>22.1-50.1 (n=128)	>50.1-134.1 (n=128)	>134.1 (n=128)
Median OS, months				
Sipuleucel-T	41.3	27.1	20.4	18.4
Control	28.3	20.1	15.0	15.6
Difference	13.0	7.0	5.4	2.8
HR (95% CI)	0.51 (0.31-0.85)	0.74 (0.47-1.17)	0.81 (0.52-1.24)	0.84 (0.55-1.29)

- Earlier use of sipuleucel-T prior to abiraterone/enzalutamide is preferred, given lack of short term benefits on PSA, disease control and possible improved survival impact earlier in the disease course

Schellhammer et al Urology 2013


## Sipuleucel-T

- FDA Approved April 2010
- Toxicities are mild, infusion related: fever, chills
- Slightly higher risk of spinal cord compression in men treated with sipuleucel-T, thus consideration of spinal imaging (MRI) in men with higher volume spinal disease
- Ideally used early with lower volume disease or before numerous other therapies
- No impact on PSA or radiographic response, PFS
- NCCN category 1 recommendation if asymptomatic to minimally symptomatic (no opiates for cancer pain), no liver metastases, life expectancy >6 mo, ECOG 0-1


## Illustrative Case #1 (cont)

- Immunotherapy:
  - June 2013 – Sipuleucel-T x 3 infusions
    - Leuprolide continued
    - Denosumab q4weeks
- Surveillance post-sipuleucel-T:
  - **July 2014** – Bone scan: progression of osseous metastatic disease
  - CT a/p: Unchanged subcentimeter pulmonary nodules and mesenteric nodes
  - **PSA 114 ng/mL, testosterone 15 ng/dL**
  - LDH 261, Alk phos 264, Hgb 13.1, LFTs NL
  - Remains minimally symptomatic
- Discussion point:
  - Options and timing for next systemic therapy in mCRPC—  
abiraterone/enzalutamide vs docetaxel vs radium-223 vs clinical trials

## Enzalutamide: Second Generation Androgen Receptor Inhibitor



## PREVAIL: Chemo-Naïve CRPC




**N=1717, randomized 1:1 Enzalutamide vs placebo**

All subgroups benefited  
 rPFS 3.9→NYR (15-19 mo)  
 PSA PFS 2.8→11.2 months  
 OS updated 2015 35.3 vs. 31.3 months (HR 0.77 p=0.002)  
 PSA 50/90% or greater decline in 78/47%  
 RECIST responses in 59%  
 Time to chemo: 28 vs. 10.8 months  
 QOL responses in 40 vs. 23%, TTQOL decline 11.3 vs. 5.6 mo

Beer, Armstrong et al NEJM 2014

## Activity of Enzalutamide in Men with mCRPC Based on Pattern of Spread





Evans et al Eur Urol 2016

# Chemo-Naïve Enzalutamide Risks

Adverse Events	Enzalutamide (N=871)		Placebo (N=844)	
	All Grades	Grade ≥3	All Grades	Grade ≥3
number of patients (percent)				
<b>Most common adverse events<sup>a</sup></b>				
Fatigue	310 (36)	16 (2)	218 (26)	16 (2)
Back pain	235 (27)	22 (3)	187 (22)	25 (3)
Constipation	193 (22)	4 (<1)	145 (17)	3 (<1)
Arthralgia	177 (20)	12 (1)	135 (16)	9 (1)
Decreased appetite	158 (18)	7 (<1)	136 (16)	6 (1)
Hot flush	157 (18)	1 (<1)	65 (8)	0
Diarrhea	142 (16)	2 (<1)	119 (14)	3 (<1)
Hypertension	117 (13)	59 (7)	35 (4)	19 (2)
Asthenia	113 (13)	11 (1)	67 (8)	8 (1)
Fall	101 (12)	12 (1)	45 (5)	6 (1)
Weight loss	100 (11)	5 (1)	71 (8)	2 (<1)
Edema peripheral	92 (11)	2 (<1)	69 (8)	3 (<1)
Headache	91 (10)	2 (<1)	59 (7)	3 (<1)
<b>Specific adverse events</b>				
Any cardiac adverse event	88 (10)	24 (3)	66 (8)	18 (2)
Atrial fibrillation	16 (2)	3 (<1)	12 (1)	5 (1)
Acute coronary syndromes	7 (1)	7 (1)	4 (<1)	2 (<1)
Acute renal failure	32 (4)	12 (1)	38 (5)	12 (1)
Ischemic or hemorrhagic cerebrovascular event	12 (1)	6 (1)	9 (1)	3 (<1)
Elevation in alanine aminotransferase level	8 (1)	2 (<1)	5 (1)	1 (<1)
Seizure	1 (<1) <sup>†</sup>	1 (<1) <sup>†</sup>	1 (<1)	0

Beer, Armstrong et al NEJM 2014

## Abiraterone Acetate + Prednisone




Attard et al JCO 2008

# Abiraterone Acetate

- Superiority over prednisone demonstrated post-docetaxel and in chemo-naïve men with mCRPC
- Dose is 1000 mg daily without food plus prednisone 5 mg bid
- Improved OS accompanied by improvements in QOL, pain, PFS, response rates, and fewer adverse events than placebo
- Prevention of pain, performance status deterioration, need for chemotherapy improved pre-docetaxel
- Abiraterone acetate with prednisone is now FDA approved for men with metastatic CRPC prior to docetaxel

OS 30.2→34.7 months  
HR 0.81 p=0.0033



Ryan et al Lancet Oncol 2015  
Ryan et al NEJM 2012

## Abiraterone acetate side effects

	Abiraterone acetate group (n=542)				Placebo group (n=540)*			
	Grades 1-2	Grade 3	Grade 4	Grade 5	Grades 1-2	Grade 3	Grade 4	Grade 5
Fluid retention/oedema	161 (30%)	6 (1%)	0 (0%)	0 (0%)	123 (23%)	8 (1%)	1 (<1%)	0 (0%)
Hypokalaemia	87 (16%)	12 (2%)	2 (<1%)	0 (0%)	59 (11%)	10 (2%)	0 (0%)	0 (0%)
Hypertension	104 (19%)	25 (5%)	0 (0%)	0 (0%)	57 (11%)	17 (3%)	0 (0%)	0 (0%)
Cardiac disorders	81 (15%)	35 (6%)	6 (1%)	4 (<1%)	73 (14%)	17 (3%)	3 (<1%)	3 (<1%)
Atrial fibrillation	20 (4%)	8 (1%)	2 (<1%)	1 (<1%)	22 (4%)	5 (<1%)	0 (0%)	0 (0%)
ALT increased	40 (7%)	28 (5%)	4 (<1%)	0 (0%)	23 (4%)	3 (<1%)	1 (<1%)	0 (0%)
AST increased	47 (9%)	18 (3%)	0 (0%)	0 (0%)	21 (4%)	5 (<1%)	0 (0%)	0 (0%)

Data are n (%). ALT=alanine aminotransferase. AST=aspartate aminotransferase. \* Before crossover.

Ryan et al Lancet Oncol 2015

## Abiraterone vs. Enzalutamide in Chemotherapy Naïve Men with mCRPC

	Abiraterone Acetate	Enzalutamide
Requires prednisone	Y	N
May cause mineralocorticoid excess	Y	N
Evaluated in visceral disease	Y (post-chemo only)	Y (pre/post chemo)
Major side effects	Hypertension, hypokalemia, LFTs, edema, some cardiac, fatigue, hot flush	Hypertension, rare seizures (<0.2%), some cardiac, fatigue, falls (19%), hot flush
Grade 3-4 AE Risk (%)	48%	43%
PSA response rate (>50%)	62%	78%
Radiographic response rate	36%	59%
rPFS	16.5 months	15-18 months
OS	34.7 months	35.3 months
Time to chemotherapy	25 months	28 months

Zhang, Armstrong et al *Exp Opin Pharmacother* 2015

## Timing and Selection of Secondary Androgen Receptor (AR)-Directed Therapies

- Choice of abiraterone vs. enzalutamide cannot be dictated based on differences in efficacy
  - Similar OS, PFS from cross-trial comparisons
  - Enzalutamide has been evaluated in men with visceral metastases in the chemo-naïve setting
  - Both considered category 1 recommendations in NCCN guidelines
- Therefore choice is based on differential toxicity
  - Abiraterone acetate for seizure-prone men and those more frail elderly (>75y) men at high risk for falls
  - Enzalutamide for men with significant CV risk factors, contraindications to prednisone, brittle diabetes and metabolic syndrome, contraindications to prednisone

## Practical Aspects of Enzalutamide Use

- NCCN category 1 recommendation in 2016 in the mCRPC setting regardless of prior docetaxel, pattern of spread, symptoms
- Prescription is for 4 40-mg capsules taken once daily, with or without food
- I recommend home BP monitoring given the 7% risk of severe HTN with enzalutamide (160/100) of unclear cause
- Exercise encouraged to reduce fall risk
- No driving restrictions given rare seizure risk but important to avoid enzalutamide in patients with a prior history of seizures or epilepsy or those men at very high risk of seizures (brain tumors, prior major strokes, CNS metastases, taking concurrent medications that lower the seizure threshold)

## Practical Aspects of Abiraterone Acetate with Prednisone Use

- NCCN category 1 recommendation in 2016 in the mCRPC setting regardless of prior docetaxel, symptoms
- Prescription is for 4 500-mg tablets taken once daily, 1 hour prior to food intake or 2 hours after food (water OK)
  - Taking with food increases bioavailability substantially, may increase toxicity
- I recommend home BP monitoring given the 5-10% risk of severe HTN with abiraterone (160/100) due to mineralocorticoid excess
  - Eplerenone may reverse this (mineralocorticoid antagonist)
- Exercise encouraged to reduce fall risk, fatigue
- Liver function and electrolyte, renal monitoring every 6 weeks initially, then every 12 weeks
  - Treatment of fluid retention, hypokalemia is common
- Pre-treatment cardiac evaluation reasonable in patients with significant underlying congestive heart failure (CHF), coronary artery disease (CAD), or arrhythmias




## Practical Aspects of Abiraterone/ Enzalutamide Use: Follow-up

- I check PSA at 6 weeks and then every 12 weeks and perform CT, bone scans every 12 weeks
- Radiographic progression typically follows PSA progression, but occasionally radiographic progression can be observed first
- Bone scan progression can be misclassified due to healing response, so confirmation of additional new lesions over time is needed before declaring progression based on bone scan alone
- CT remains important to document soft tissue/visceral metastases which can develop over time
- I do not stop abiraterone/enzalutamide for PSA-only progression because there is clear clinical benefit of these agents for multiple other disease manifestations (pain, QOL, radiologic)


## Bone Scans in CRPC

1. Difficult to interpret
2. Images osteoblast activity
3. Healing may appear more intense!
4. New lesions are best measures of progression vs. flare (within clinical context)
5. Confirmation scans showing continued additional new lesions required—flare is common (40% with abiraterone/enzalutamide!)
6. Prostate Cancer Working Group 2 Guidelines are new criteria for determining progression
7. Often will be performed on site and centrally along with clinical read
8. **Thus, misclassification of progression is common!**




## Cross-Resistance in the Clinic

- **Enzalutamide after abiraterone** can result in PSA responses (>50% decline) but this was observed in <1/3 of men in the post-docetaxel CRPC setting with a short TTP of 4 months and rare radiographic responses
- Similar for abiraterone after enzalutamide and in pre-docetaxel setting
- Response to enzalutamide was not possible to predict based on prior response to abiraterone




Schrader Eur Urol 2013  
Zhan, Armstrong CGUC 2015



## AR-v7 and Cross-Resistance

Measured through a circulating tumor cell (CTC) assay and an AR-v7 rt-PCR based probe




Limitation: not yet externally validated in a multicenter trial

Antonarakis et al NEJM September 2014

## AR-v7 and Cross-Resistance

Note: CTC AR-V7 test has not yet been externally validated and thus remains a research biomarker at this time (ongoing studies)



HR, 6-16!



Associated with prediction of poor OS or clinical benefit

Antonarakis et al NEJM September 2014

## Illustrative Case #2

- 69yo male with prostate cancer:
  - cT2b G9 PSA 2.4 ng/mL
  - Metastatic workup: negative
- RP: pT3a GS4+3, tertiary 5, R1
- Adjuvant XRT
- One year later, PSA rise from 0.1→9→44
- Restaging scans:
  - CT/BS shows multiple bone mets and bulky RP nodes up to 7.7cm
- ADT + docetaxel initiated

## Images



## Illustrative Case #2 (cont)

- Restaging after docetaxel induction chemotherapy/ADT reveals resolution of adenopathy, persistent bone metastases, PSA is 2.0
- Within 12 months, PSA rises to 14 and diffuse bone pain develops. Staging confirms additional new bone lesions in axial spine, no visceral/nodal metastases
- Patient is treated with enzalutamide and responds but progresses within 6 months

National  
Comprehensive  
Cancer  
Network®

**NCCN Guidelines Version 2.2016**

**Prostate Cancer**

### How to treat Men with mCRPC who progress following docetaxel?

**SUBSEQUENT SYSTEMIC THERAPY FOR M1 CRPC\*\***

Prior therapy  
enzalutamide/  
abiraterone

↕

No visceral  
metastases

↕

Prior therapy  
docetaxel

- Docetaxel with prednisone (category 1)<sup>x</sup>
- Abiraterone<sup>l</sup> with prednisone
- Enzalutamide
- Radium-223 for symptomatic bone metastases (category 1)
- Sipuleucel-T if asymptomatic or minimally symptomatic, no liver metastases, life expectancy >6 mo, ECOG 0-1
- Clinical trial
- Other secondary hormone therapy
  - ▶ Antiandrogen
  - ▶ Antiandrogen withdrawal
  - ▶ Ketoconazole ± hydrocortisone
  - ▶ Corticosteroid
  - ▶ DES or other estrogen<sup>z</sup>
- Best supportive care


- Enzalutamide (category 1)
- Abiraterone<sup>l</sup> with prednisone (category 1)
- Radium-223 for symptomatic bone metastases (category 1)
- Cabazitaxel with prednisone (category 1)<sup>x</sup>
- Sipuleucel-T if asymptomatic or minimally symptomatic, no liver metastases, life expectancy >6 mo, ECOG 0-1
- Clinical trial
- Docetaxel rechallenge<sup>x</sup>
- Alternative chemotherapy (mitoxantrone with prednisone)<sup>x</sup>
- Other secondary hormone therapy
  - ▶ Antiandrogen
  - ▶ Antiandrogen withdrawal
  - ▶ Ketoconazole ± hydrocortisone
  - ▶ Corticosteroid
  - ▶ DES or other estrogen<sup>z</sup>
- Best supportive care

PROG-12

© National Comprehensive Cancer Network, Inc.® 2016. All Rights Reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

## Range of $\alpha$ -emitting Radiopharmaceutical Compared with $\beta$ -emitter

Short range of  $\alpha$ -particles reduces bone marrow exposure



Henriksen G et al. *Cancer Res.* 2002.

## Radium Targets Osteoblastic Bone Metastases by Acting as a Calcium

# Periodic Table of the Elements

1

H

3

Li

4

Be

11

Na

12

Mg

19

K

20

Ca

37

Rb

38

Sr

55

Cs

56

Ba

87

Fr

88

Ra

hydrogen

alkali metals

alkali earth metals

transition metals

poor metals

nonmetals


noble gases

rare earth metals


																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																														</
--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

Radium (Ra 223 dichloride) prescribing information, 2013.

## ALSYMPCA: Phase III Study Design




## ALSYMPCA Updated Analysis: OS



Parker et al NEJM 2013



## Predictors of Radium-223 Benefit?



## Radium-223 Updated Analysis Adverse Events (AEs) of Interest


Patients with AEs n, (%)	All Grades		Grades 3 or 4	
	Radium-223 n = 600	Placebo n = 301	Radium-223 n = 600	Placebo n = 301
<b>Hematologic</b>				
Anemia	187 (31)	92 (31)	77 (13)	39 (13)
Neutropenia	30 (5)	3 (1)	13 (2)	2 (1)
Thrombocytopenia	69 (12)	17 (6)	38 (6)	6 (2)
<b>Non-Hematologic</b>				
Bone pain	300 (50)	187 (62)	125 (21)	77 (26)
Diarrhea	151 (25)	45 (15)	9 (2)	5 (2)
Nausea	213 (36)	104 (35)	10 (2)	5 (2)
Vomiting	111 (19)	41 (14)	10 (2)	7 (2)
Constipation	108 (18)	64 (21)	6 (1)	4 (1)

The safety of taxane chemotherapy following radium-223  
has not been well characterized

Parker et al NEJM 2013




## Radium-223 and Prior Docetaxel Use



Hoskin et al Lancet Oncol 2015

## Subgroup Analysis of Hazard Ratios for Death in the Two Study Groups



Parker et al NEJM 2013

## Radium-223: Summary

### Administration:

- Once every 4 weeks for 6 months
- 60 second IV infusion
- Given by radiation oncologist or nuclear medicine radiologist
- Enteric excretion
- No pre-medication, no post-medication
- CBC check before each treatment

### Clinical Benefit:
















- Primary endpoint of improvement in symptomatic SRE
- 3.6 month benefit in OS
- Perhaps greater in men with high alkaline phosphatase
- Should be considered in symptomatic men with bone-predominant mCRPC
- Consider spinal imaging for epidural disease in men with high burden of disease and rapid progression; palliative EBXRT should be used if high risk for spinal cord compression
- No head to head data vs. docetaxel yet, and optimal timing/sequencing/combination with hormonal therapies and chemotherapy is currently being established

## NCCN Guidelines

- Radium-223 recommended for men with symptomatic bone-predominant mCRPC
- Can be used before or after docetaxel given similar survival benefit
- Patients should be followed carefully for bone marrow toxicity prior to dosing and over time
- Concurrent use of hormonal therapies, external beam palliative radiation, steroids are reasonable given the lack of drug interactions and safety, palliative goals

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Prostate Cancer (Version 2.2016). © 2016 National Comprehensive Cancer Network, Inc.

## NCCN Summary Recommendations: M1 CRPC

	NO VISCERAL METASTASES	WITH VISCERAL METASTASES
Abiraterone with prednisone		
Corticosteroid		
Docetaxel with prednisone		
Enzalutamide		
Ketoconazole		
Ketoconazole + hydrocortisone		
Mitoxantrone with prednisone		—
Radium-223		—
Sipuleucel-T		—

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for Prostate Cancer (Version 2.2016).  
© 2016 National Comprehensive Cancer Network, Inc.



## Q&A SESSION



National  
Comprehensive  
Cancer  
Network®

## Closing Remarks

- If you participated with a group of peers, a list of everyone who attended in your group must be submitted within two weeks of the activity in order for the participants to be eligible to receive credit. Lists can be sent to [education@nccn.org](mailto:education@nccn.org) and should contain full contact information for each participant, including first and last name, credentials, mailing address, phone number, and e-mail address.
- If you have not individually registered, please register at:  
<http://www.cvent.com/d/6fgrc4>.
- An e-mail will be sent within 5-7 business days with instructions on how to login to complete post-test and evaluation. These must be completed in order to receive a CE certificate. Contact [education@nccn.org](mailto:education@nccn.org) should you not receive this e-mail within 5 business days.
- For notification of upcoming NCCN educational events:



Visit [NCCN.org/events](http://NCCN.org/events)



Join our group on LinkedIn: [NCCN Conferences and Meetings Group](#)



Follow us on Twitter: [@NCCNMeetings](#) and [@NCCNnews](#) and [@JNCCN](#)



National  
Comprehensive  
Cancer  
Network®

## NCCN Member Institutions

